L'Oreal says weight loss drugs are impacting beauty and skincare sales
The beauty giant's CEO says the use of GLP-1s is "a very important phenomenon for us".
Beauty giant L'Oreal says the rise of weight loss drugs has affected beauty and skincare sales, as it designs products to specifically target some side-effects of rapid weight loss.
The company's head Nicolas Hieronimus said the beauty market was proving resilient in a challenging global context and that the use of GLP-1s was "a very important phenomenon for us".
He told an investor call that the rise in their use was "having an impact on beauty consumption and skin care consumption in particular".
Hieronimus said L'Oreal's brands SkinCeuticals and Kiehl's have products "that have been designed to work alongside and complement GLP-1 and its side-effects on skin sagging" and other effects related to rapid weight loss.